Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02287038 · ClinicalTrials.gov registry record · Phase 4
Atomoxetine in Veterans With Comorbid ADHD/PTSD
A Phase 4 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 4
- Development phase
- 44
- Enrollment target
NCT02287038: Completed Phase 4 study, sponsored by VA Office of Research and Development.
NCT02287038 is a Phase 4 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 44 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02287038, a Phase 4 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 44 participants
- Enrollment target
Study Summary
The current available treatments for PTSD are not fully effective for cognitive symptoms of PTSD and have high drop-out and poor engagement, two factors found to be most indicative of overall return to functioning for patients with PTSD. The proposed study directly addresses this knowledge gap by conducting a pilot, fixed-dose, randomized, double-blind, placebo-controlled, and cross-over trial using atomoxetine (ATX) as an add-on medication to other therapies to testing the efficacy of ATX in reducing ADHD cognitive symptoms among veterans with comorbid ADHD/PTSD. Successful completion of this pilot clinical trial may build a platform for future large scale double-blind, placebo-controlled studies using either atomoxetine or other cognitive enhancing medications.
Interventions
- DRUG Atomoxetine 80 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2014-10-15 |
| Est. Completion | 2017-04-14 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02287038
The ClinicalTrials.gov registry entry for NCT02287038 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atomoxetine 80 MG is the first listed.
NCT02287038 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02287038 about?
NCT02287038 is a clinical study titled "Atomoxetine in Veterans With Comorbid ADHD/PTSD". The current available treatments for PTSD are not fully effective for cognitive symptoms of PTSD and have high drop-out and poor engagement, two factors found to be most indicative of overall return to functioning for patients with PTSD. The proposed study directly addresses this knowledge gap by co...
What is the current status of trial NCT02287038?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 44 participants. The study started on 2014-10-15. Estimated completion is 2017-04-14.
What interventions are being tested in trial NCT02287038?
The interventions under investigation include: Atomoxetine 80 MG (DRUG).
Who is sponsoring clinical trial NCT02287038?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.